1Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat, 2004, 11(2): 97-107.
2Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatol, 2006, 45(4): 529-538.
3Murray KF, Carithers RL, Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation[J]. Hepatology, 2005, 41(6): 1407-1432.
4Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma[J]. Semin Liver Dis, 2005, 25 (Suppl 1 ): 40-47.
6Dienstag JL, Goldin RD, Heathcote E J, et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterology, 2003, 124(1): 105-117.
7Chang TT, Liaw YF, Wu SS, et al. Long-term enteeavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-893.
8Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531.
9Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B[J]. Hepatology, 2000, 31(1): 207-210.
10Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection[J]. J Hepatol, 2000, 33(2): 301-307.
二级参考文献15
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
7Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：829
3Cholongitas E, Goulis J, Arsos G, et al. Association Between Ratio of Sodium to Potasium in, Random Urine Samples and Renal Dysfunc- tion and Mortality in Patients with Decompensated Cirrhosis [ J ]. CIin Gastroenterol Hepato1,2013,7 ( 11 ) : 862 - 867.
4Zimmermann HW, Reuken PA, Koch A, et al. Soluble urokinase plas- minogen activator receptor (suPAR) is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality[J]. J Intern Med,2013,1 (274) :86 - 100.
5Zantra A J, Hoffman JM, Matt KS, et al. An examination of individual differences in the relationship between interpersonal stress and dis- ease activity among women with rheumatoid arthritis [ J ]. Arthritis Care Res,1998,11 (4) :271 -279.
6Dubowitz T, Ghosh-Dastidar MB, Collins R, et al. Food policy re- search: We need better measurement, better study designs, and rea- sonable and measured actions based on the available evidence [ J ]. Obesity ( Silver Spring) ,2012,21 ( 1 ) :5 - 6.
7White CJ, Jaff MR. Catch-22: Carotid stenting is safe and effective (Food and Drug Administration) but is it reasonable and necessary (Centers for Medicare and Medicaid Services)? [J]. JACC Cardio- vasc Interv,2012,5 (6) :694 - 696.
8Andrews GJ,Evans J, McAlister S. Creating the right therapy vibe': Relational performances in holistic medicine[ J]. Soc Sci Med,2013, (83) :99 - 109.
9Sawni A, Singh A, Complementary, holistic, and integrative medi- cine: ache [ J ]. Pediatr Rev,2013,34 ( 2 ) :91 - 93.
